Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Mechanistic Studies of Cytokine Release Syndrome (CRS) with Roles of Interferon-Gamma (IFN-g) and Tumor Necrosis Factor Alpha (TNF-α) While Maintaining CAR-T Function in Vitro

Parmeshwar N Amatya, Jingyu Xiang, Julie O'Neal, Julie K. Ritchey, Alun J Carter, Matthew L. Cooper, John DiPersio

Blood (2023) 142 (Supplement 1): 2086.

https://doi.org/10.1182/blood-2023-187449

Published: 2023

Journal Articles

An “Off-the-Shelf” CD2 Universal CAR-T Therapy Combined with a Long-Acting IL-7 for T-Cell Malignancies

Jingyu Xiang, Jessica Devenport, Alun J Carter, Karl Staser, Michael P. Rettig, Miriam Y Kim, Julie O'Neal, Julie K. Ritchey, Feng Gao, Garrett Rettig, Rolf Turk, Alexandra Wolfarth, Byung Ha Lee, Matthew L. Cooper, John F. DiPersio

Blood (2023) 142 (Supplement 1): 764.

https://doi.org/10.1182/blood-2023-181087

Published: 2023

Journal Articles

The Dual PI3Kdg Inhibitor Duvelisib Potently Inhibits Cytokine Release Syndrome (CRS) While Maintaining CAR-T Function

Parmeshwar N. Amatya, Reyka G. Jayasinghe, Alun J. Carter, Matthew L. Cooper, Jonathan A. Pachter, John F. DiPersio, Julie K. Ritchey

Blood (2022) 140 (Supplement 1): 12686–12687.

https://doi.org/10.1182/blood-2022-167715

Published: 2022

Journal Articles

The Dual PI3Kδγ Inhibitor Duvelisib Potently Inhibits IL-6 Production and Cytokine Release Syndrome (CRS) While Maintaining CAR-T Function in Vitro and In Vivo

Parmeshwar N Amatya, PhD, Alun J Carter, PhD BSc, Julie K Ritchey, Jessica Niswonger, Matthew L Cooper, PhD, Jonathan A Pachter, PhD, John F. DiPersio, MD PhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-139904

Published: 2020

Journal Articles

Identification of Small Molecule Kinase Inhibitors That Potently and Reversibly Block Chimeric Antigen Receptor T Cell Proliferation and Cytotoxicity

Parmeshwar Amatya, PhD, Matthew L. Cooper, PhD, Alun J Carter, PhD BSc, John F. DiPersio, MD PhD

Blood (2019) 134 (Supplement_1): 2068.

https://doi.org/10.1182/blood-2019-126165

Published: 2019

Journal Articles

Therapeutic Potential of AO-176, a Next Generation Humanized CD47 Antibody, for Hematologic Malignancies

W. Casey Wilson, PhD, Myriam N Bouchlaka, BS, PhD, Ben J Capoccia, PhD, Ronald R Hiebsch, BS, Michael J Donio, BS, Robyn J Puro, PhD, Alun J Carter, PhD, Prabir Chakraborty, PhD, Pamela T Manning, PhD, Robert W Karr, MD, Vicki Sung, PhD, Daniel S Pereira, PhD

Blood (2018) 132 (Supplement 1): 4180.

https://doi.org/10.1182/blood-2018-99-118456

Published: 2018

NARROW

Mechanistic Studies of Cytokine Release Syndrome (CRS) with Roles of Interferon-Gamma (IFN-g) and Tumor Necrosis Factor Alpha (TNF-α) While Maintaining CAR-T Function in Vitro

An “Off-the-Shelf” CD2 Universal CAR-T Therapy Combined with a Long-Acting IL-7 for T-Cell Malignancies

The Dual PI3Kdg Inhibitor Duvelisib Potently Inhibits Cytokine Release Syndrome (CRS) While Maintaining CAR-T Function

The Dual PI3Kδγ Inhibitor Duvelisib Potently Inhibits IL-6 Production and Cytokine Release Syndrome (CRS) While Maintaining CAR-T Function in Vitro and In Vivo

Identification of Small Molecule Kinase Inhibitors That Potently and Reversibly Block Chimeric Antigen Receptor T Cell Proliferation and Cytotoxicity

Therapeutic Potential of AO-176, a Next Generation Humanized CD47 Antibody, for Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Mechanistic Studies of Cytokine Release Syndrome (CRS) with Roles of Interferon-Gamma (IFN-g) and Tumor Necrosis Factor Alpha (TNF-α) While Maintaining CAR-T Function in Vitro

An “Off-the-Shelf” CD2 Universal CAR-T Therapy Combined with a Long-Acting IL-7 for T-Cell Malignancies

The Dual PI3Kdg Inhibitor Duvelisib Potently Inhibits Cytokine Release Syndrome (CRS) While Maintaining CAR-T Function

The Dual PI3Kδγ Inhibitor Duvelisib Potently Inhibits IL-6 Production and Cytokine Release Syndrome (CRS) While Maintaining CAR-T Function in Vitro and In Vivo

Identification of Small Molecule Kinase Inhibitors That Potently and Reversibly Block Chimeric Antigen Receptor T Cell Proliferation and Cytotoxicity

Therapeutic Potential of AO-176, a Next Generation Humanized CD47 Antibody, for Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only